Loading stock data…
$1.37-0.01 (-0.72%)
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States.
Pulmatrix, Inc. in the Healthcare sector is trading at $1.37 with a market capitalization of $5M. The stock is currently near its 52-week low of $1.16, remaining 22.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.05M↑ | -$1.29M↓ | -$908,000↓ | -$866,000↑ | -$1.55M |
| Net Income | -$1.04M↑ | -$1.17M↓ | -$928,000↓ | -$877,000↑ | -$1.55M |
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered...